To explore the regulatory role of immune factors in interstitial cystitis/bladder pain syndrome (IC/BPS).

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000032176

Enrollment

Unknown

Registered

2020-04-22

Start date

2020-04-20

Completion date

Unknown

Last updated

2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial cystitis/bladder pain syndrome

Interventions

IC/BPS group vs. healthy control group:N/A

Eligibility

Sex/Gender

Female

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 20-70 years; 2. Patients with interstitial cystitis with corresponding clinical manifestations.

Exclusion criteria

Exclusion criteria: Patients who meet one of the following conditions: 1. The patient is suffering from cystitis and has urinary tract infection within one month; 2. Have used or are using immunosuppressants or antibiotics and other drugs; 3. Patients with autoimmune diseases: SLE, etc.; 4. Have bladder tumor or ever had; 5. Had bladder surgery; 6. Serious urinary obstruction; 7. Have used the medicine bladder perfusion or bladder injection treatment; 8. Self intermittent or long-term catheterization.

Design outcomes

Primary

Measure	Time frame
The ratio of immune factors and the number of immune cells;	—

Countries

China

Contacts

Public ContactDeyi Luo

West China hospital of sichuan university

luodeyi1985@163.com+86 18380453539

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026